These results agree with the recent observation that GSK3 inhibition results in glioma cell death through a mechanism that depends on c-MYC activation, decreased NF-κB activity, and an alteration of intracellular glucose metabolism [29]. This evidence concerns the gene MYC and central nervous system cancer.